Cryotherapy Effect, Nail Toxicity, Peripheral Neuropathy
Conditions
Brief summary
This study will determine the efficacy of cryotherapy to prevent paclitaxel-induced peripheral neuropathy and nail changes in women with breast cancer.
Detailed description
Women with breast cancer receiving paclitaxel will complete the Brief Pain Inventory(BPI), Neuropathic Pain Syndrome Inventory (NPSI)while a member of the research team will conduct an assessment of their nails. Once complete, cryotherapy will be administered 15 minutes prior to the paclitaxel infusion, continuously during and then 15 minutes after completion of the paclitaxel for a total of 90 minutes. Cyrotherapy will be delivered using Elasto-gel mitts and Rapid relief slippers. These items will be changed 45min after initiation to ensure coldness. There will be two arms of the study. One arm will include subjects who will wear one slipper/one mitt on their foot/hand while the other foot/hand will serve as a control. The other arm will include subjects who will have cryotherapy to both hands and feet. . This process will be repeated for a total of 12 times in conjunction with 12 doses of paclitaxel. At time point 13, during a routine visit to their oncologist, the subjects nails will be reassessed along with completion of the BPI and NPSIA total of 25 subjects will be enrolled in each arm.
Interventions
OTHERcryotherapy
cryotherapy will be delivered
Sponsors
Parkview Health
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
There are 2 arms to the study.The Elasto-gel mitt and Rapid Relief slipper will be placed either on one hand/foot or both based on the patient's medical oncologist. All subjects will have a standardized onset/duration of therapy which includes the following : * 15 minutes prior to the paclitaxel infusion, * Continuously during the paclitaxel infusion, * 15 minutes after completion of paclitaxel for a total of 90 minutes.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Females 18 or older * Histologically confirmed diagnosis of breast cancer * Receiving neo-adjuvant or adjuvant dose-dense anthracycline (AC) plus taxane-based chemotherapy or paclitaxel in combination with trastuzumab and pertuzumab
Exclusion criteria
* Prior taxane therapy * Prior oxaliplatin therapy * Non-English speaking * History of peripheral neuropathy, i.e., Buerger's disease * History of diabetes mellitus * Pre-existing peripheral neuropathy from other conditions, e.g., Raynaud's disease, Guillain-Barre, Miller Fisher Syndrome * Hand, nail or foot conditions, e.g., hand/foot syndrome, arthritis, hammer toe, carpal tunnel, bunions, deformities * Alcohol abuse (history/current) * Current medication usage of opioids, anti-depressants, anti-convulsants, glutamines, vitamin B12
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Numbness,tingling,pain ,nail toxicities | 13 weeks | absence of numbness and tingling in the treated hands/feet * If there is an absence of pain in the treated hands/feet * If there is an absence of nail changes in the treated hands/feet |
Countries
United States
Outcome results
None listed